News & Events

Trasis is nominated for the Trends Gazelles 2021, in the category of Large Companies for the Province of Liège. 

For 20 years now, the editors of Trends-Tendances and Trends have been selecting between 50 and 250 Trends Gazelles in each province. These fast-growing companies are not only a source of energy for our economy but also a real inspiration for entrepreneurs.

The Trends Gazelle title is recognized in the business world because of its national reputation and regional recognition.

We are happy to announce that we will exhibit again during the 33^rd Annual European Association of Nuclear Medicine Congress, which will take place in Vienna, from 17 to 21 October 2020. You can already contact our team to make an appointment!  

We will also have the opportunity to meet you in September during the next JFMN (Journée Francophones de Médecine Nucléaire) organized in Paris, and during the CSH (Convergences Santé Hôpital) organized in Nantes in October.

The SNMMI is already over, time flew by fast ! We were so happy to meet you there.

The show went great this year, we ended up with a lot of promising projects. The FDA approval of Trasis FDOPA's process was among other the icing of the cake.

If you missed us but would like to get updated on Trasis' products, feel free to contact us.

Our team will be delighted to meet you at the ISRS in Beijing this year.

You can make an appointment or meet us on our booth.

• The appointment will give you a chosen moment with one of our expert. Email us and we will schedule a meeting with our team.
• 6&7 are our booth #, we would be happy to tell you how to upgrade your lab to the latest technologies.

The EANM already seems so far away... We really miss the intensity of having a booth full of people every single day! This edition might be over on the paper but it is still running through our heads. We then couldn't resist to share some of the best moments with you.

Düsseldorf, 15 October 2018 : Trasis' Community Meeting.

Düsseldorf, 15 October 2018.

Prostate cancer is the second leading cause of cancer death for men in many parts of the world. For imaging, PSMA-based radio tracers target the PSMA  (Prostate Specific Membrane Antigen) transmembrane glycoprotein, which is strongly upregulated in prostate cancer cells. In this way, the PET tracer provides important molecular information on cancer and metastases localization within the prostate.

AllinOne family versatility proven